Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03482648 · ClinicalTrials.gov registry record · Phase 1

First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers

A Phase 1 study, sponsored by Bridge Biotherapeutics.

Completed
Registry status
Phase 1
Development phase
80
Enrollment target

NCT03482648: Completed Phase 1 study, sponsored by Bridge Biotherapeutics.

NCT03482648 is a Phase 1 study that has completed, run by Bridge Biotherapeutics. The registered enrollment target is 80 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT03482648, a Phase 1 study, has completed, sponsored by Bridge Biotherapeutics.

COMPLETED
Registry status
Phase 1
Development phase
80 participants
Enrollment target

Study Summary

This clinical trial is the first-in-human study of BBT-401-1S. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of BBT-401-1S in healthy adult subjects.

Primary Outcome

To assess the safety and tolerability of single and multiple ascending oral doses of BBT-401-1S in healthy adult subjects.

Interventions

  • DRUG Placebo
  • DRUG BBT-401-1S, Single dose
  • DRUG BBT-401-1S, Multiple doses

Trial Details

FieldValue
Enrollment Target 80 participants
Start Date 2018-03-20
Est. Completion 2018-10-03
Phase Phase 1
Bridge Biotherapeutics

7 total trials

What the finished NCT03482648 record still lists

NCT03482648 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (33% higher).

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT03482648 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03482648 about?

NCT03482648 is a clinical study titled "First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers". This clinical trial is the first-in-human study of BBT-401-1S. The purpose of this phase 1 study is to assess the safety and tolerability of single and multiple ascending oral doses of BBT-401-1S in healthy adult subjects.

What is the current status of trial NCT03482648?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 80 participants. The study started on 2018-03-20. Estimated completion is 2018-10-03.

What interventions are being tested in trial NCT03482648?

The interventions under investigation include: Placebo (DRUG), BBT-401-1S, Single dose (DRUG), BBT-401-1S, Multiple doses (DRUG).

Who is sponsoring clinical trial NCT03482648?

This trial is sponsored by Bridge Biotherapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03482648's enrollment target sits among peer trials

80 672nd of 2000 higher than 1,305 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-07-11

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01243931 · 80 participants · NA

    Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy

  • NCT01659203 · 80 participants · Phase 1

    Proton or Photon RT for Retroperitoneal Sarcomas

  • NCT01803451 · 80 participants · Early Phase 1

    Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass

  • NCT01964859 · 80 participants · Phase 2

    Feasibility Study for Fibroblast Autologous Skin Grafts

Similar registry start date

  • NCT03383419 · started 2018-03-20 · Phase 2

    Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients

  • NCT03471260 · started 2018-03-19 · Phase 1

    Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

  • NCT03457493 · started 2018-03-22 · Phase 1

    The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy

  • NCT03418038 · started 2018-03-23 · Phase 2

    Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Source: ClinicalTrials.gov NCT03482648, the US trial registry maintained by the National Library of Medicine. NCT03482648 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.